These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 16490849)

  • 41. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
    Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
    Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases.
    Rütter A; Luger TA
    Curr Opin Investig Drugs; 2002 May; 3(5):713-9. PubMed ID: 12090544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous immunoglobulin induced-nephropathy: a complication of IVIG therapy.
    Ahsan N
    J Nephrol; 1998; 11(3):157-61. PubMed ID: 9650125
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology.
    Prins C; Gelfand EW; French LE
    Acta Derm Venereol; 2007; 87(3):206-18. PubMed ID: 17533485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impairment of renal function after intravenous immunoglobulin.
    Soares SM; Sethi S
    Nephrol Dial Transplant; 2006 Mar; 21(3):816-7. PubMed ID: 16399766
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of myasthenia gravis with intravenous immunoglobulin G (IVIG)].
    Lavrnić DB; Stojanović V; Marinković Z; Pavlović S; Vidaković A; Apostolski S
    Srp Arh Celok Lek; 1995; 123(5-6):146-8. PubMed ID: 17974459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe cutaneous adverse drug reaction to leflunomide: a report of two cases.
    Jian X; Guo G; Ruan Y; Lin D; Li X
    Cutan Ocul Toxicol; 2008; 27(1):5-9. PubMed ID: 18330828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
    Harbo T; Andersen H; Jakobsen J
    Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Usefulness of high-dose intravenous human immunoglobulins treatment for refractory recurrent pericarditis.
    Moretti M; Buiatti A; Merlo M; Massa L; Fabris E; Pinamonti B; Sinagra G
    Am J Cardiol; 2013 Nov; 112(9):1493-8. PubMed ID: 23972350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
    Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
    Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Maculopapular rash in the convalescent phase of Kawasaki disease: case series and literature review.
    Takeuchi M; Oda Y; Suzuki I
    Eur J Pediatr; 2013 Mar; 172(3):405-7. PubMed ID: 23192460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Acute encephalitis complicating acute polyradiculoneuritis].
    Attarian S; Trebuchon A; Azulay JP; Pouget J
    Rev Neurol (Paris); 2002 Apr; 158(4):470-2. PubMed ID: 11984491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hemolysis upon intravenous immunoglobulin transfusion.
    Padmore RF
    Transfus Apher Sci; 2012 Feb; 46(1):93-6. PubMed ID: 22169381
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effects of three intravenous gamma globulin regimens on Kawasaki disease and relevant coronary complication rates in pediatric patients: a comparative study].
    DU ZD; Zhao D; DU JB; Lu S; Yi JM; Hou AC; Zhou ZS; Ding GF;
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3119-21. PubMed ID: 18269869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neurological complications of intravenous immunoglobulin (IVIg) therapy: an illustrative case of acute encephalopathy following IVIg therapy and a review of the literature.
    Mathy I; Gille M; Van Raemdonck F; Delbecq J; Depré A
    Acta Neurol Belg; 1998 Dec; 98(4):347-51. PubMed ID: 9922823
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Serum levels of interleukin-6 and interleukin-10 in patients with multiple sclerosis during intravenous immunoglobulin infusion].
    Kazibutowska Z; Motta E; Huć M; Strzała-Orzeł M; Woźnik G
    Wiad Lek; 2006; 59(9-10):626-9. PubMed ID: 17338118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
    Bussel JB; Hanna K;
    Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
    Yang Y; Xu J; Li F; Zhu X
    Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.
    Daoud Y; Amin KG; Mohan K; Ahmed AR
    Ann Pharmacother; 2005 Dec; 39(12):2003-8. PubMed ID: 16264064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.